Companies - GoINPHARMA
Friday, 14 December 2018 - 0:39

Companies

Bausch Health (former Valeant) invests $200m in buying Synergy Pharma

Bausch Health–former Valeant–has announced it has acquired Synergy Pharma for $200m, after the company had already gone into voluntary liquidation and started filing for bankruptcy. Synergy’s key asset is surely Trulance, a therapy approved by FDA and Chinese authorities for…

Novo Nordisk increases research activity in new Oxford R&D center

Denmark-based Novo Nordisk yesterday announced a one-year cooperation agreement with Britain-based biotech E-Therapeutics. As part of the agreement, Novo will be entitled to use the drug discovery platform developed by E-Therapeutics to search for Type-2 diabetes treatments. The Denmark-based group…

Gilead turns the page

US-based biotech Gilead Sciences has announced that it has appointed veteran Daniel O’Day as next CEO. O’Day, 54, was born in the US and has been working for Roche for 30 years, in three different continents and in positions requiring…

Boehringer Ingelheim announces 327 job cuts in France

Germany-based Boehringer Ingelheim yesterday announced to French trade unions a restructuring plan including at least 327 job cuts in France. The decision addresses the need to completely reorganize Boehringer Ingelheim in France, which has 2,800 employees, many of which in…

Fresenius lowers guidance and shares decline 15%

Germany-based group Fresenius’ CEO Stephan Sturm has announced during a conference call to investors that the management has lowered the guidance for the near future and now expects the company won’t be able to reach the sales and profit target…

AstraZeneca’s Imfinzi fails another Phase III clinical trial

Astra Zeneca CEO Pascal Soriot’s position is more and more difficult. The French manager in 2015 convinced shareholders to reject a $118bn acquisition offer by Pfizer, arguing that independence would mean higher financial return to shareholders. The strategy developed by…

An analysis of big pharma’s pipelines

Consultancy Phrma yesterday published a report on big pharma companies’ pipelines. According to the report, as many as 289 new gene therapies are currently being developed, 111 of which specifically targeting cancer. The rest of therapies is meant to treat…

Excellent first trading day for Moderna Therapeutics: $604m raised

Biotech Moderna Therapeutics yesterday made its IPO (Nasdaq),an event watched closely by analysts and investors, being the largest IPO ever from a biotech group.  Moderna’s listing was a success for its management: 26.3m shares were sold at $23 per share,…

Sanofi announces 670 job cuts in France

Sanofi France’s head Guillaume Leroy yesterday assembled the three French trade unions and informed them that the group intends to cut as many as 670 jobs in France before 2020. Cuts will mainly affect IT Service employees, but also HR…

Japan’s Taisho submits its offer to buy BMS’ Upsa (€1bn)

Italian daily Il Messaggero some days ago reported 4 bids for France-based Upsa, put up for sale by US-based group Bristol-Myers Squibb. The article added that pharmaceutical group Angelini made a more profitable bid than private equities PAI Partners and…

GSK acquires Tesaro for $5.1bn

After having announced job cuts, reorganizing plans and pipeline rationalization for countless times, GlaxoSmithKline’s CEO Emma Walmsley today announced, as trading started in Europe, her first acquisition. Indeed, GSK informed it has acquired US-based biotech Tesaro for $5.1bn in cash….

Gilead reports new data on efficacy of CAR-T therapy Yescarta

Gilead has reported results from ZUMA-1 clinical trial, designed to assess the breakthrough investigational therapy Yescarta (axicabtagene ciloleucel), on patients with large B-cell lymphoma. The treatment has been developed by Kite, the biotech acquired by Gilead in 2017. The trial…

Takeda ready to dismiss assets for a total $10bn

Japan economic and financial daily Nihon KeizaiShimbun yesterday reported that Takeda Pharmaceutical is about to divest assets for $10bn in order to offset the debt–which has reached $48bn now–built up by acquiring Shire for $62bn. The newspaper also reports a…

Angelini most likely buyer of Upsa (Bristol-Myers Squibb)

Italian daily Il Messaggero today has reported that Angelini is the most likely candidate to acquire its French competitor Upsa, belonging to US-based Bristol-Myers Squibb. The article mentions as sources the banks hired to manage the transaction. Four companies have…

Positive momentum for Teva: generic to Rituxan approved

Positive momentum for Teva, which has announced it has obtained the FDA approval for Truxima, a biosimilar to Rituxan (MabThera), a blockbuster by Genentech-Roche. Truxima has been developed by its South Korea-based partner Celltrion for the treatment of non-Hodgkin lymphoma….

Bayer announces 12,000 job cuts globally

Germany-based group Bayer today has announced in a press release that it will cut as many as 12,000 jobs all over the world before 2021 in order to improve its profitability. The job cuts will account for almost 10% of…

Gilead can now attempt at takeover of Galapagos

The Dutch economic and financial daily Het Financieele Dagblad today has reviewed the press release issued by Belgian-Dutch biotech company Galapagos to announce that Van Herk Investments’ stake in the company has decreased to 9.91% due to dilution. As a…

Loxo Oncology’s cancer drug approved

Stamford, Connecticut-based Loxo Oncology has informed that FDA has approved Vitrakvi (larotrectinib), the first TRK inhibitor for the treatment of solid cancer types with genetic mutations in receptors. Vitrakvi is the first cancer treatment with a nearly agnostic approach to…

Unilever ready to acquire Horlick from GSK for about $4bn

Britain-based Unilever and GlaxoSmithKline are reportedly in exclusive talks now over a sale of India-based Holrlick–a subsidiary of GlaxoSmithKline’s–for an approximate $4bn. An acquisition of Horlick is reportedly consistent with Unilever’s latest strategic moves; moreover, it would increase its presence…

Private equity Ardian gains control of Neopharmed Gentili

Italian economic-financial daily Il Sole 24 Ore has reported today that Mediulanum Farmaceutici has sold its subsidiary Neopharmed Gentili to private equity Ardian. Neopharmed in 2017 generated sales of €192m. (Source Il Sole24Ore)

Excellent Phase III results for Vertex’s new cystic fibrosis therapy

Boston, US-based Vertex Pharmaceuticals today has announced extremely positive results from two Phase III clinical trials assessing VX-659 on patients with cystic fibrosis. The results show that patients treated with VX-659 have lung functionality improved by 14% and good therapy…

Xio might sell Lumenis to CVC for 1 billion dollars

Private equity XIO is seeking to sell Lumenis, Israel-based medical devices producer for plastic surgery. Xio acquired Lumenis in 2015 for $520m and its value has almost doubled to $1bn three years after the acquisition. The Israeli company boasts a…

Private equities step forward to acquire Nestlé Skin Health

The Sunday Times today has reported that Nestlé’s Skin Health division has attracted interest from private equity firms CVC Capital Partners, Carlyle Group and TPG. Nestlé’s asset marketing skin health products has been put up for sale due to pressure…

Behind the scenes of Bayer-Monsanto deal

The Wall Street Journal today has published a long article rehearsing the history of Monsanto acquisition by Germany-based Bayer. The deal is the result of new CEO Werner Baumann’s perseverance: for years, he had been seeking to convince the top…